Fig. 1: Testing, S-gene targeted taction, and clinical outcomes during the study period.
From: Immune escape and attenuated severity associated with the SARS-CoV-2 BA.2.86/JN.1 lineage
Panels illustrate A the number of outpatient cases diagnosed daily from tests processed on Thermo Fisher TaqPath COVID-19 Combo Kit (TF) assays or non-TF assays; B the daily frequency of TF-tested specimens yielding positive results with S gene detected (non-BA.2.86 lineages) or S-gene target failure (BA.2.86-derived lineages); C the daily frequency of outpatient cases with positive SARS-CoV-2 testing results (organized by date of test) who experienced emergency department (ED) presentations within 14 days of testing, stratified according to presence or absence of acute respiratory infection (ARI) diagnoses associated with their ED presentation; D the daily frequency of outpatient cases with positive SARS-CoV-2 testing results (organized by date of test) who experienced hospital admission within 28 days of testing, stratified according to presence or absence of ARI diagnoses associated with their hospital admission; and E the daily frequency of outpatient cases with positive SARS-CoV-2 testing results (organized by date of test) who experienced intensive care unit (ICU) admission, initiation of mechanical ventilation, or death within 60 days of testing. Analyses include data from 46,067 eligible individuals throughout the study period, including 7,694 with TF-tested specimens. Source data to replicate the figure are provided as a Source Data file (fig1_source.xlsx).
